Gene News and Research

Latest Gene News and Research

Roche, Exiqon join marketing forces for RealTime ready assays, microRNA PCR systems

Roche and Exiqon join marketing forces for Roche Applied Science's RealTime ready assays and Exiqon`s miRCURY LNA Universal RT microRNA qPCR system. As indicated by respective links on their websites, each system will complement the cooperator's product portfolio.

21 Jul 2010

INRA Genomic Platform core facility now provides services on Fluidigm's BioMark System for Genetic Analysis

Fluidigm Corporation today announced that the Toulouse Midi-Pyrénées Genomic Platform - Genotoul INRA core facility is now providing a wide range of services on a BioMark™ System for Genetic Analysis to a wide range of French researchers. These services include SNP genotyping, gene expression analysis and digital PCR quantification of DNA libraries for next-generation sequencing. The INRA has been validating the performance of the system on several projects over the past year.

21 Jul 2010

University of Luebeck becomes part of Metaminer Cardiac Partnership

GeneGo, Inc., a leading provider of databases, software and services in systems biology and chemistry, announced today that Dr. Salah Mohamed in Department of Cardio and Thoracic Vascular Surgery at the University of Luebeck and his team will be part of the Metaminer Cardiac Partnership. Dr. Mohamed is published within 6 different reputed Scientific American Journals in connection with Biomarker Discovery work performed for the American Heart Association.

21 Jul 2010

Affymetrix introduces Axiom Custom Genotyping Arrays

Affymetrix, Inc. today announced that it has launched Axiom™ Custom Genotyping Arrays, the newest addition to the Axiom Genotyping Solution. Researchers can now leverage Affymetrix' Axiom Genomic Database, the world's largest collection of validated common and rare SNPs, to create custom arrays containing 50,000 to as many as 2.6 million SNPs. This inherent flexibility allows researchers to conduct genome-wide association, replication, fine mapping, and candidate gene studies on a single platform.

21 Jul 2010

Researchers receive $12M NCI grant to identify biological pathways that lead to prostate cancer risk

Researchers at the USC Norris Comprehensive Cancer Center have received a $12 million National Cancer Institute grant to lead a multi-institution international project aimed at identifying new biological pathways critical to the development and potential treatment of prostate cancer.

21 Jul 2010

La Jolla Institute forms partnership to investigate potential new therapy for sickle cell disease

Researchers from the La Jolla Institute for Allergy & Immunology have joined forces with the Dana-Farber Cancer Institute in Boston and Washington University in St. Louis to investigate a potential new therapy for sickle cell disease, a severe and chronic illness affecting more than 70,000 Americans and several million people worldwide.

21 Jul 2010

CHLA receives $410,000 grant for 'first in childhood leukemia' multi-site study

J. Eric Bubbers, PhD, of the Saban Research Institute at Childrens Hospital Los Angeles, has received a $410,000 grant from Phase One Foundation. The award will fund a "first in childhood leukemia" multi-site study in children with relapsed or refractory acute lymphocytic leukemia (ALL) or acute myelogenous leukemia (AML). Dr. Bubbers is the administrative director of Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL), an academic research consortium consisting of 33 member institutions in four countries.

21 Jul 2010

Meridian Bioscience third-quarter net sales decrease 11% to $33.9 million

Net sales for the third quarter of fiscal 2010 were $33,857,000 as compared to $38,240,000 for the same period of the prior fiscal year, a decrease of 11%. Net earnings for the third quarter of fiscal 2010 were $6,424,000 or $0.16 per diluted share, both decreases of 24%, compared to the third quarter of fiscal 2009. (Net earnings include $673,000 in Bioline acquisition costs or $0.01 per diluted share.) Diluted common shares outstanding for fiscal 2010 and 2009 were 41,151,000 and 41,191,000, respectively.

20 Jul 2010

Quantitative capabilities of Helicos' single-molecule sequencing technology demonstrated

Helicos BioSciences Corporation today announced a publication entitled "Amplification-free digital gene expression profiling from minute cell quantities" appearing on line in Nature Methods co-authored by Dr. Daniel A. Haber and colleagues from Massachusetts General Hospital. The paper demonstrates the quantitative capabilities of Helicos' single-molecule sequencing technology and its potential to reveal important genomic differences when minimal numbers of cells are available for analysis.

20 Jul 2010

NanoViricides presents study results of nanoviricides anti-Ebola agents

NanoViricides, Inc. reports that the results of the evaluation of several of its nanoviricides anti-Ebola agents were presented July 17th at the Annual Meeting of the American Society for Virology, July 17-21, at Montana State University, Bozeman, MT. Dr. Corinne Scully delivered the presentation, which was entitled "Polymeric Micelle Nanomaterials as Antiviral Compounds For Ebola Virus Infection."

20 Jul 2010

New approach to understand different cancer subtypes

An international team led by St. Jude Children's Research Hospital scientists finds unique combinations of cells and mutations lie at the heart of cancer subgroup revealed for the first time in a pediatric brain tumor

20 Jul 2010

Parkinson's medication produces serious side effects in the form of involuntary, jerky movements: Research

One in every 100 elderly people suffers from Parkinson's disease, a disease of the nervous system with symptoms including stiffness and shaking. The standard medication used to treat Parkinson's is Levodopa, a drug that initially has major benefits but can later also produce serious side effects in the form of involuntary, jerky movements. A research group at Lund University has now found a way to study what it is in the brain that causes these side effects.

20 Jul 2010

Cellectis bioresearch introduces new technology to develop cell-based assays for HTS studies

Cellectis bioresearch, a specialist in genome customization and a subsidiary of Cellectis, today announced the publication of a scientific study describing a novel method, based on meganuclease-driven targeted integration, for the generation of stable cell lines compatible with high throughput screening (HTS).The study demonstrated Cellectis bioresearch's technology to be faster, more reliable and efficient in deriving cell-based assays for HTS studies than classical methods.

20 Jul 2010

Researchers discover new gene regulation, DNA behavior of breast cancer cells

Cancer researchers have discovered a previously unknown type of gene regulation and DNA behavior in breast cancer cells that may lead to better insight about environmental exposure to estrogen-like compounds. A new study, published in the journal Genome Research by researchers at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), provides the first evidence that cells can regulate many genes at once by looping their DNA, contributing to cancer when it goes awry. In this study, the gene regulation was discovered in breast cancer cells as a response to the hormone estrogen and resulted in the silencing of 14 genes at one time.

20 Jul 2010

Researchers discover genetic explanation for non-diabetic kidney disease in African-Americans

Kidney disease is a growing public health problem, with approximately half a million individuals in the United States requiring dialysis treatments to replace the function of their failed kidneys. The problem is particularly acute among African-Americans, whose rates of kidney disease are four times higher than those of European Americans.

20 Jul 2010

Researchers identify a mechanism that explains different phases of CML progression

Researchers at Duke University Medical Center have identified a mechanism that could explain how patients move into the worst phase of chronic myelogenous leukemia.

20 Jul 2010

Over-expression of CIB1 protein triggers biochemical processes that lead to cardiac hypertrophy: Study

Scientists have identified a key molecular regulator of cardiac hypertrophy (enlargement of the heart) that may provide a therapeutic target for a major risk factor of heart failure and early death.

19 Jul 2010

Tet 1 protein helps stem cells renew themselves and stay pluripotent: Researchers

Take a skin cell from a patient with Type 1 diabetes. Strip out everything that made it a skin cell, then reprogram it to grow into a colony of pancreatic beta cells. Implant these into your patient and voilà! She's producing her own insulin like a pro.

19 Jul 2010

Researchers to receive $1.2M from Susan G. Komen for the Cure for breast cancer research

Four researchers from Detroit, Michigan's Barbara Ann Karmanos Cancer Institute and Wayne State University will receive a total of $1.2 million from Susan G. Komen for the Cure to help advance research to better detect, prevent and eliminate breast cancer. The $1.2 million awarded to these outstanding scientists is part of the $59 million portfolio of research grants that Susan G. Komen for the Cure has awarded this year alone to scientists across the globe to help accelerate innovative breast cancer research.

17 Jul 2010

GABA disrupts working memory in neurofibromatosis type 1 patients

Imagine if your brain lost its working memory - the ability to hold and manipulate information in your mind's eye. That's the plight faced by millions of people with neurofibromatosis type 1, or NF1. The genetic condition affects one in 3,500 people and is the most common cause of learning disabilities.Now a UCLA research team has uncovered new clues about how NF1 disrupts working memory. Published in the July 12 online edition of Proceedings of the National Academy of Sciences, the findings suggest a potential drug target for correcting NF1-related learning disabilities.

17 Jul 2010

Gene News and Research

Latest Gene News and Research

Roche, Exiqon join marketing forces for RealTime ready assays, microRNA PCR systems

INRA Genomic Platform core facility now provides services on Fluidigm's BioMark System for Genetic Analysis

University of Luebeck becomes part of Metaminer Cardiac Partnership

Affymetrix introduces Axiom Custom Genotyping Arrays

Researchers receive $12M NCI grant to identify biological pathways that lead to prostate cancer risk

La Jolla Institute forms partnership to investigate potential new therapy for sickle cell disease

CHLA receives $410,000 grant for 'first in childhood leukemia' multi-site study

Meridian Bioscience third-quarter net sales decrease 11% to $33.9 million

Quantitative capabilities of Helicos' single-molecule sequencing technology demonstrated

NanoViricides presents study results of nanoviricides anti-Ebola agents

New approach to understand different cancer subtypes

Parkinson's medication produces serious side effects in the form of involuntary, jerky movements: Research

Cellectis bioresearch introduces new technology to develop cell-based assays for HTS studies

Researchers discover new gene regulation, DNA behavior of breast cancer cells

Researchers discover genetic explanation for non-diabetic kidney disease in African-Americans

Researchers identify a mechanism that explains different phases of CML progression

Over-expression of CIB1 protein triggers biochemical processes that lead to cardiac hypertrophy: Study

Tet 1 protein helps stem cells renew themselves and stay pluripotent: Researchers

Researchers to receive $1.2M from Susan G. Komen for the Cure for breast cancer research

GABA disrupts working memory in neurofibromatosis type 1 patients

eBook: Using iPSCs models for human disease research and drug discovery eBook

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca